Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company based in Burlingame, California, develops immune modulators for cancers and autoimmune diseases, with key products including soquelitinib and ciforadenant. Founded in 2016, it employs 28 people and focuses on innovative immunotherapy approaches.